| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11065256 | STERISCIENCE | Administration and dosage of diaminophenothiazines |
Jan, 2039
(14 years from now) | |
| US11065265 | STERISCIENCE | Compositions of fosaprepitant and methods of preparation |
Jan, 2039
(14 years from now) | |
Focinvez is owned by Steriscience.
Focinvez contains Fosaprepitant Dimeglumine.
Focinvez has a total of 2 drug patents out of which 0 drug patents have expired.
Focinvez was authorised for market use on 22 August, 2023.
Focinvez is available in solution;intravenous dosage forms.
The generics of Focinvez are possible to be released after 11 January, 2039.
Drugs and Companies using FOSAPREPITANT DIMEGLUMINE ingredient
Market Authorisation Date: 22 August, 2023
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
More Information on Dosage
FOCINVEZ family patents
